Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACT-335827 是一种可口服的、脑渗透性 orexin 1 型 (orexin type 1) 受体选择性拮抗剂。ACT-33582 作用于 OXR1 和 OXR2 的 IC50值分别是 6 nM 和 417 nM。ACT-33582 可用于神经系统疾病的相关研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 7,980 | 35日内发货 | ||
50 mg | ¥ 32,200 | 35日内发货 |
产品描述 | ACT-335827 is an orally available, brain-penetrant orexin type 1 receptor selective antagonist. ACT-33582 acts on OXR1 and OXR2 with IC 50 values of 6 nM and 417 nM, respectively. ACT-33582 can be used in studies related to neurological disorders [1]. |
体外活性 | ACT-335827 (0-10 μM, 2 h) is active on OXR-1 and OXR-2 with the Kb values of 41 nM and 560 nM, the IC 50 values of 120 nM and 2300 nM, respectively in CHO cells [1]. |
体内活性 | ACT-335827 (oral gavage, 30-100 mg/kg, once) can reduce the fear-induced startle response without affecting motor or cognitive function in rats [1]. ACT-335827 (oral administration, 300 mg/kg, everyday, 4 weeks) has less effect on metabolic syndrome (MetS), such as diet-induced obesity (DIO) in male Wistar rats [2]. Animal Model: Rats [1] Dosage: 30, 100 or 300 mg/kg Administration: Oral gavage; once Result: Reduced fear-induced startle response at 300 mg/kg. Decreased stress-induced elevated body temperature at 300 mg/kg and accelerated heat rate at 100 or 300 mg/kg but no effect on locomotion and blood pressure. Animal Model: Male Wistar rats weighing160-180g [2] Dosage: 300 mg/kg Administration: Oral administration; everyday; 4 weeks Result: Reduced preference for high fat/sweet diets but no effect on absolute energy intake. Increased water intake and HDL relative to total cholesterol. Resulted in a 4% weight gain compared to the control group. |
分子量 | 518.64 |
分子式 | C31H38N2O5 |
CAS No. | 1354039-86-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ACT 335827 1354039-86-3 ACT335827 ACT-335827 Inhibitor inhibitor inhibit